Get the up-to-date PrimerAn Introduction to CSLCitation Style Language 1.0.1... 2025 now

Get Form
citation style language schema raw master Preview on Page 1

Here's how it works

01. Edit your citation style language schema raw master online
Type text, add images, blackout confidential details, add comments, highlights and more.
02. Sign it in a few clicks
Draw your signature, type it, upload its image, or use your mobile device as a signature pad.
03. Share your form with others
Send primeran via email, link, or fax. You can also download it, export it or print it out.

The best way to edit PrimerAn Introduction to CSLCitation Style Language 1.0.1... in PDF format online

Form edit decoration
9.5
Ease of Setup
DocHub User Ratings on G2
9.0
Ease of Use
DocHub User Ratings on G2

Adjusting paperwork with our comprehensive and intuitive PDF editor is easy. Follow the instructions below to fill out PrimerAn Introduction to CSLCitation Style Language 1.0.1... online easily and quickly:

  1. Log in to your account. Log in with your email and password or register a free account to test the service before upgrading the subscription.
  2. Import a document. Drag and drop the file from your device or import it from other services, like Google Drive, OneDrive, Dropbox, or an external link.
  3. Edit PrimerAn Introduction to CSLCitation Style Language 1.0.1.... Easily add and highlight text, insert pictures, checkmarks, and signs, drop new fillable fields, and rearrange or remove pages from your document.
  4. Get the PrimerAn Introduction to CSLCitation Style Language 1.0.1... accomplished. Download your modified document, export it to the cloud, print it from the editor, or share it with other people via a Shareable link or as an email attachment.

Benefit from DocHub, one of the most easy-to-use editors to rapidly handle your paperwork online!

be ready to get more

Complete this form in 5 minutes or less

Get form

Got questions?

We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.
Contact us
The success rate (i.e. absence of any PONV symptoms after application of ondansetron in a patient with established PONV) is 40% with 1 mg, and 45% with 4 mg. The number-needed-to-treat to prevent nausea with 4 mg is 16 (number- needed-to-treat to prevent vomiting/retching 6.4).
Patients at moderate to high risk for PONV benefit from the administration of a prophylactic antiemetic agent that blocks one or more of these receptors. Effective agents include transdermal scopolamine, prochlorperazine, promethazine, droperidol, ondansetron, dolasetron, granisetron, and dexamethasone.
The currently available antiemetic drugs for the treatment and prevention of PONV include the 5-hydroxytryptamine (5-HT 3) receptor antagonists, neurokinin-1 (NK-1) receptor antagonists, corticosteroids, butyrophenones, metoclopramide, phenothiazine, prochlorperazine, antihistamines, and anticholinergics ( Table 4).
PONV Risk Factors The following are risk factors for PONV: Female gender History of PONV History of motion sickness Non-smoker Intended administration of opioids for post-operative analgesia.
Antiemetics in specific circumstances Consider using low-dose domperidone (does not cross the blood-brain barrier), cyclizine or ondansetron. Metoclopramide and prochlorperazine are contraindicated due to the risk of exacerbation of parkinsonism.

People also ask

Barhemsys is a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for: prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class.
General Management Ensure good oxygenation and normal blood pressure. Give IV fluids if dehydrated. Administer anti-emetic early when patient is nauseated rather than waiting for patient to before treating PONV (see drug therapy section below). If cause of PONV is known, correct if possible.
Generally, uncomplicated PONV rarely goes beyond 24 hours post-operatively. Problematic PONV however is more multifactorial in origin and can be difficult to treat effectively. Patients at risk of this should be identified by the anaesthetist and may be given prophylactic anti-emetic treatment.